DC
VNDA icon

Diametric Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Diametric Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,700
Closed -$114K – 371
2024
Q4 		$114K Sell
23,700
-1,300
-5% -$6.24K 0.08% 269
2024
Q3 		$117K Hold
25,000
– – 0.06% 338
2024
Q2 		$141K Buy
+25,000
New +$129K 0.08% 296
2023
Q4 		– Sell
-10,144
Closed -$43.8K – 391
2023
Q3 		$43.8K Buy
+10,144
New +$56.4K 0.02% 310

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Diametric Capital's VNDA Position: Q1 2025 in Review

Diametric Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2025, closing a stake of 23,700 shares — an estimated $114K sold.

Diametric Capital first reported a position in VNDA in Q3 2023 and held it in 4 quarters. The position peaked at $141K in Q2 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q1 2025.

  • Diametric Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Diametric Capital sold 23,700 Vanda Pharmaceuticals shares in Q1 2025, an estimated $114K.
  • Diametric Capital first reported a position in Vanda Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Diametric Capital's Vanda Pharmaceuticals position peaked at $141K in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2025.

Based on Diametric Capital's 13F filing for Q1 2025, filed 14 May 2025.